Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma

BACKGROUND: Nab-paclitaxel–gemcitabine combination significantly improved overall survival over gemcitabine in metastatic pancreatic adenocarcinoma. A phase 1b trial was performed (ClinicalTrials.gov number, NCT01730222) to determine the recommended phase 2 dose (RP2D) of nab-paclitaxel in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Reni, Michele, Balzano, Gianpaolo, Zanon, Silvia, Passoni, Paolo, Nicoletti, Roberto, Arcidiacono, Paolo Giorgio, Pepe, Gino, Doglioni, Claudio, Fugazza, Clara, Ceraulo, Domenica, Falconi, Massimo, Gianni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973162/
https://www.ncbi.nlm.nih.gov/pubmed/27404453
http://dx.doi.org/10.1038/bjc.2016.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973162/
https://www.ncbi.nlm.nih.gov/pubmed/27404453
http://dx.doi.org/10.1038/bjc.2016.209

Ejemplares similares